KalVista Pharmaceuticals (KALV) Common Equity (2014 - 2025)

KalVista Pharmaceuticals has disclosed Common Equity across 12 years of filings, most recently posting $40.8 million for Q3 2025.

• Common Equity for Q3 2025 came in at $40.8 million, down 76.39% year-over-year; the trailing twelve-month figure through Jul 2025 was $40.8 million (down 76.39% YoY), and the FY2025 annual result was $95.4 million, down 53.82% from the prior year.
• Common Equity came in at $40.8 million for Q3 2025 at KalVista Pharmaceuticals, down from $95.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $257.2 million in Q2 2021 to a low of $40.8 million in Q3 2025.
• The 5-year median for Common Equity is $164.4 million (2024), against an average of $157.4 million.
• Across the five-year window, Common Equity soared 255.05% in 2022 and slumped 76.39% in 2025, its largest moves.
• KalVista Pharmaceuticals' Common Equity stood at $227.5 million in 2021, then plunged by 36.78% to $143.8 million in 2022, then fell by 20.42% to $114.4 million in 2023, then jumped by 43.61% to $164.4 million in 2024, then tumbled by 75.18% to $40.8 million in 2025.
• The last three Common Equity figures came in at $40.8 million (Q3 2025), $95.4 million (Q2 2025), and $164.4 million (Q4 2024), per Business Quant data.